Print this page
-
A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumamb in Advanced Cancers.
Protocol: 172401Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Any Site -
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors.
Protocol: 172404Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects.
Protocol: 192001Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site -
Biospecimen Procurement for Cancer Immunotherapy at Rutgers Cancer Institute.
Protocol: 192002Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site
Breast
Cervix
Lung
Stomach -
Screening Protocol for Clinical Trial Eligibility.
Protocol: 192101Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site -
Long Term Follow Up for Subjects Treated with Gene Therapy Cell Products at Rutgers Cancer Institute.
Protocol: 192103Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Anus
Cervix
Larynx
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital -
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation.
Protocol: 192301Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Any Site